Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 38317584)

  • 1. Referred molecular testing as a barrier to optimal treatment decision making in metastatic non-small cell lung cancer: Experience at a tertiary academic institution in Canada.
    Grafham GK; Craddock KJ; Huang WY; Louie AV; Zhang L; Hwang DM; Parmar A
    Cancer Med; 2024 Feb; 13(3):e6886. PubMed ID: 38317584
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular Testing Turnaround Time for Non-Small Cell Lung Cancer in Routine Clinical Practice Confirms Feasibility of CAP/IASLC/AMP Guideline Recommendations: A Single-center Analysis.
    DiStasio M; Chen Y; Rangachari D; Costa DB; Heher YK; VanderLaan PA
    Clin Lung Cancer; 2017 Sep; 18(5):e349-e356. PubMed ID: 28377205
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biomarker testing and tissue journey among patients with metastatic non-small cell lung cancer receiving first-line therapy in The US Oncology Network.
    Robert NJ; Espirito JL; Chen L; Nwokeji E; Karhade M; Evangelist M; Spira A; Neubauer M; Bullock S; Walberg J; Cheng SK; Coleman RL
    Lung Cancer; 2022 Apr; 166():197-204. PubMed ID: 35313244
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biomarker testing and time to treatment decision in patients with advanced nonsmall-cell lung cancer.
    Lim C; Tsao MS; Le LW; Shepherd FA; Feld R; Burkes RL; Liu G; Kamel-Reid S; Hwang D; Tanguay J; da Cunha Santos G; Leighl NB
    Ann Oncol; 2015 Jul; 26(7):1415-21. PubMed ID: 25922063
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biomarker Turnaround Times and Impact on Treatment Decisions in Patients with Advanced Non-Small Cell Lung Carcinoma at a Large Canadian Community Hospital with an Affiliated Regional Cancer Centre.
    Fleming KE; Hupel A; Mithoowani H; Lulic-Kuryllo T; Valdes M
    Curr Oncol; 2024 Mar; 31(3):1515-1528. PubMed ID: 38534948
    [No Abstract]   [Full Text] [Related]  

  • 6. Real-World Biomarker Testing Patterns in Patients With Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) in a US Community-Based Oncology Practice Setting.
    Sireci AN; Krein PM; Hess LM; Khan T; Willey J; Ayars M; Deyoung K; Bhaskar S; Mumuney G; Coutinho A
    Clin Lung Cancer; 2023 Jul; 24(5):429-436. PubMed ID: 37080814
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world patterns of biomarker testing and targeted therapy in de novo metastatic non-small cell lung cancer patients in the US oncology network.
    Nadler E; Vasudevan A; Wang Y; Ogale S
    Cancer Treat Res Commun; 2022; 31():100522. PubMed ID: 35189530
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fast In-House Next-Generation Sequencing in the Diagnosis of Metastatic Non-small Cell Lung Cancer: A Hospital Budget Impact Analysis.
    Silas U; BlĂĽher M; Bosworth Smith A; Saunders R
    J Health Econ Outcomes Res; 2023; 10(1):111-118. PubMed ID: 37389301
    [No Abstract]   [Full Text] [Related]  

  • 9. Factors Associated With Receipt of Molecular Testing and its Impact on Time to Initial Systemic Therapy in Metastatic Non-Small Cell Lung Cancer.
    Osazuwa-Peters OL; Wilson LE; Check DK; Roberts MC; Srinivasan S; Clark AG; Crawford J; Chrischilles E; Carnahan RM; Campbell WS; Cowell LG; Greenlee R; Abbott AM; Mosa ASM; Mandhadi V; Stoddard A; Dinan MA
    Clin Lung Cancer; 2023 Jun; 24(4):305-312. PubMed ID: 37055337
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Benefits of Implementing Reflex Genomic Analysis for Nonsmall Cell Lung Cancer.
    Smith BF; Hampel KJ; Sidiropoulos N
    J Appl Lab Med; 2024 Jan; 9(1):28-40. PubMed ID: 38167774
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of Reflex EGFR/ ALK Testing on Time to Treatment of Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer.
    Cheema PK; Menjak IB; Winterton-Perks Z; Raphael S; Cheng SY; Verma S; Muinuddin A; Freedman R; Toor N; Perera J; Anaka M; Victor JC
    J Oncol Pract; 2017 Feb; 13(2):e130-e138. PubMed ID: 28029301
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biomarker Testing, Treatment, and Outcomes in Patients With Advanced/Metastatic Non-Small Cell Lung Cancer Using a Real-World Database.
    Bhandari NR; Hess LM; He D; Peterson P
    J Natl Compr Canc Netw; 2023 Sep; 21(9):934-944.e1. PubMed ID: 37673115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interventional pulmonology use of cell-free DNA assay for metastatic non-small cell lung cancer: the UC Davis experience.
    Phan C; Jespersen F; Weipert C; Li T; Yoneda KY
    Ther Adv Respir Dis; 2022; 16():17534666221135324. PubMed ID: 36346075
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trends in real-world biomarker testing and overall survival in US patients with advanced non-small-cell lung cancer.
    Wu N; Ge W; Quek RG; Gleeson M; Pouliot JF; Dietz H; Jalbert JJ; Harnett J; Antonia SJ
    Future Oncol; 2022 Dec; 18(39):4385-4397. PubMed ID: 36656547
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular testing patterns in metastatic non-small cell lung cancer.
    MacLean E; Louder A; Saverno K; Smith G; Mardekian J; Brunis C; Ward M; Sweetman R; Pasquale M
    Am J Manag Care; 2016 Feb; 22(2):e60-7. PubMed ID: 26881321
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real world treatment patterns, healthcare resource use and costs in patients with advanced or metastatic non-small cell lung cancer by
    Vadagam P; Waters D; Lee I; Chen J; Tian D; Near AM; Lyle D; Vanderpoel J
    J Med Econ; 2024; 27(1):219-229. PubMed ID: 38269536
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Consensus recommendations for optimizing biomarker testing to identify and treat advanced
    Cheema PK; Gomes M; Banerji S; Joubert P; Leighl NB; Melosky B; Sheffield BS; Stockley T; Ionescu DN
    Curr Oncol; 2020 Dec; 27(6):321-329. PubMed ID: 33380864
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adequacy of small biopsy and cytology specimens for comprehensive genomic profiling of patients with non-small-cell lung cancer to determine eligibility for immune checkpoint inhibitor and targeted therapy.
    Faber E; Grosu H; Sabir S; San Lucas FA; Barkoh BA; Bassett RL; Luthra R; Stewart J; Roy-Chowdhuri S
    J Clin Pathol; 2022 Sep; 75(9):612-619. PubMed ID: 33952592
    [TBL] [Abstract][Full Text] [Related]  

  • 19. What, When, and How of Biomarker Testing in Non-Small Cell Lung Cancer.
    Riely GL
    J Natl Compr Canc Netw; 2017 May; 15(5S):686-688. PubMed ID: 28515244
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of time-to-treatment discontinuation of targeted therapy, immunotherapy, and chemotherapy in clinical trials of patients with non-small-cell lung cancer.
    Blumenthal GM; Gong Y; Kehl K; Mishra-Kalyani P; Goldberg KB; Khozin S; Kluetz PG; Oxnard GR; Pazdur R
    Ann Oncol; 2019 May; 30(5):830-838. PubMed ID: 30796424
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.